Donald L Weaver
Affiliation: University of Vermont
- Sentinel lymph node biopsy in breast cancer: creating controversy and defining new standardsD L Weaver
Department of Pathology, University of Vermont College of Medicine and Vermont Cancer Center, Burlington 05405 0068, USA
Adv Anat Pathol 8:65-73. 2001..Practicing pathologists will need to stay abreast of the issues and facts in order to participate in the debate and shape the future of pathologic management of sentinel nodes...
- Development of a diagnostic test set to assess agreement in breast pathology: practical application of the Guidelines for Reporting Reliability and Agreement Studies (GRRAS)Natalia V Oster
Department of Medicine, University of Washington, Seattle, WA, USA
BMC Womens Health 13:3. 2013..We use the newly developed Guidelines for Reporting Reliability and Agreement Studies (GRRAS) as a basis to report these methods...
- Sentinel lymph nodes and breast carcinoma: which micrometastases are clinically significant?Donald L Weaver
Department of Pathology, University of Vermont College of Medicine, Burlington, Vermont 05405 0068, USA
Am J Surg Pathol 27:842-5. 2003..Rigorous strategies designed to reliably detect single cells or small cell clusters in sentinel nodes remain time-intensive and cost prohibitive...
- Metastasis detection in sentinel lymph nodes: comparison of a limited widely spaced (NSABP protocol B-32) and a comprehensive narrowly spaced paraffin block sectioning strategyDonald L Weaver
Department of Pathology, University of Vermont College of Medicine, Burlington, VT 05405 0068, USA
Am J Surg Pathol 33:1583-9. 2009..7 to 4.8 mm) and the modal thickness was 2.3 mm. Although more comprehensive sectioning of SLNs detects additional micrometastases, the data suggest diminishing returns and reduced cost effectiveness for the comprehensive strategy...
- Pathology evaluation of sentinel lymph nodes in breast cancer: protocol recommendations and rationaleDonald L Weaver
Department of Pathology, University of Vermont College of Medicine, Burlington, VT, USA
Mod Pathol 23:S26-32. 2010..If we ultimately adopt more comprehensive microscopic evaluation of SLNs, the candidate sampling strategies need to be carefully considered in the context of statistically valid sampling strategies...
- Effect of occult metastases on survival in node-negative breast cancerDonald L Weaver
University of Vermont College of Medicine and Vermont Cancer Center, Department of Pathology, Burlington, VT 05405 0068, USA
N Engl J Med 364:412-21. 2011..Prospective data on clinical outcomes from randomized trials according to sentinel-node involvement have been lacking...
- Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissectionTakamaru Ashikaga
University of Vermont College of Medicine, Burlington, Vermont 05405, USA
J Surg Oncol 102:111-8. 2010....
- Surgeon training, protocol compliance, and technical outcomes from breast cancer sentinel lymph node randomized trialDavid N Krag
Department of Surgery, College of Medicine, University of Vermont, Given Building, Rm E309, 89 Beaumont Ave, Burlington, VT 05405, USA
J Natl Cancer Inst 101:1356-62. 2009..We evaluated the relationship of surgeon trial preparation, protocol compliance audit, and technical outcomes...
- Detection of occult sentinel lymph node micrometastases by immunohistochemistry in breast cancer. An NSABP protocol B-32 quality assurance studyDonald L Weaver
Department of Pathology, College of Medicine, University of Vermont, Burlington, Vermont 05405 0068, USA
Cancer 107:661-7. 2006..2 mm but not larger than 2.0 mm) or isolated tumor cell clusters (< or = 0.2 mm). This study defines the rate at which pathologists miss metastases on CK IHC of sentinel lymph nodes (SLN)...
- NSABP-32: Phase III, randomized trial comparing axillary resection with sentinal lymph node dissection: a description of the trialDavid N Krag
Department of Surgery, University of Vermont, Burlington, Vermont, USA
Ann Surg Oncol 11:208S-10S. 2004..A secondary aim of the B32 trial is to evaluate whether patients with "occult" metastases in the SNs have worse survival. Accrual is taking place at 73 institutions in North America, and 217 surgeons are enrolling patients...
- Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trialDavid N Krag
University of Vermont, College of Medicine, Burlington, VT 05405 0068, USA
Lancet Oncol 8:881-8. 2007..The aim of this paper is to report the technical success and accuracy of SLN resection plus ALND versus SLN resection alone...
- Predicting biopsy outcome after mammography: what is the likelihood the patient has invasive or in situ breast cancer?Donald L Weaver
Department of Pathology, University of Vermont College of Medicine and Vermont Cancer Center, Health Science Complex, 89 Beaumont Avenue, Burlington, Vermont 05405 0068, USA
Ann Surg Oncol 12:660-73. 2005..Although substantial effort has been devoted to estimating breast cancer risk, there have been no studies to predict outcome in women undergoing breast biopsy...
- Pathologic findings from the Breast Cancer Surveillance Consortium: population-based outcomes in women undergoing biopsy after screening mammographyDonald L Weaver
Department of Pathology, University of Vermont, Burlington, 05405, USA
Cancer 106:732-42. 2006..To the authors' knowledge, a comprehensive analysis of pathology outcomes after screening mammography, as it is practiced clinically in the U.S. general population, has not been performed...
- Selection of tumor-binding ligands in cancer patients with phage display librariesDavid N Krag
Department of Surgery and Vermont Cancer Center, University of Vermont College of Medicine, E309 89 Beaumont Avenue, Burlington, VT 05405, USA
Cancer Res 66:7724-33. 2006..The lack of toxicity and the ability to recover clones with favorable characteristics are a first step for further research with this technology in cancer patients...
- Identification of a small peptide that inhibits the phosphorylation of ErbB2 and proliferation of ErbB2 overexpressing breast cancer cellsStephanie C Pero
Department of Surgery, Vermont Comprehensive Cancer Center, College of Medicine, University of Vermont, Burlington, VT 05405, USA
Int J Cancer 111:951-60. 2004..Continuing research with this peptide includes increasing its affinity to ErbB2, evaluation of pharmacokinetics and evaluation of anti-proliferative effects with conjugate anti-cancer agents...
- Cyclin D-1, interleukin-6, HER-2/neu, transforming growth factor receptor-II and prediction of relapse in women with early stage, hormone receptor-positive breast cancer treated with tamoxifenHyman B Muss
Vermont Cancer Center, University of Vermont College of Medicine, Burlington, Vermont 05401, USA
Breast J 13:337-45. 2007..In this trial, HER-2 and CD1 proved of borderline significance as predictive factors for recurrence on tamoxifen. An SVM model that included all clinical and biologic variables correctly predicted relapse in >75% of patients...
- Pathological and molecular assessment of sentinel lymph nodes in solid tumorsDavid N Krag
Department of Surgery, Vermont Cancer Center, College of Medicine, University of Vermont, Burlington, VT 05405, USA
Semin Oncol 29:274-9. 2002..It is critical that pathologists and clinicians conduct definitive clinical research directed toward defining the role and impact that SN surgery has on each of these surgical goals...
- Nodal stage classification for breast carcinoma: improving interobserver reproducibility through standardized histologic criteria and image-based trainingRoderick R Turner
Department of Pathology, Saint John s Health Center, 1328 Twenty Second St, Santa Monica, CA 90404, USA
J Clin Oncol 26:258-63. 2008..We sought to determine whether a set of clearly defined histologic criteria could lead to reproducible nodal classification by pathologists...
- Comparison of pathologist-detected and automated computer-assisted image analysis detected sentinel lymph node micrometastases in breast cancerDonald L Weaver
University of Vermont, Vermont Cancer Center and Fletcher Allen Health Care, Burlington, Vermont 05405 0068, USA
Mod Pathol 16:1159-63. 2003..Metastases identified exclusively by computer-assisted cell detection tend to be extremely small, and the clinical significance of their identification is currently unknown...
- HER-2/neu detection in fine-needle aspirates of breast cancer: fluorescence in situ hybridization and immunocytochemical analysisBarbara G Beatty
Department of Pathology, University of Vermont College of Medicine, Burlington 05405 0068, USA
Am J Clin Pathol 122:246-55. 2004....
- The effect of tissue fixation and processing on breast cancer sizeBobbi Pritt
Department of Pathology, University of Vermont College of Medicine, Burlington, VT 05405, USA
Hum Pathol 36:756-60. 2005..One can arguably measure the size of an invasive breast cancer from either the fresh or fixed state without affecting accuracy, but caution should be exercised in relying solely on the microscopic measurements...
- The detection of isolated tumor cells in bone marrow comparing bright-field immunocytochemistry and multicolor immunofluorescenceDavid N Krag
Department of Surgery, University of Vermont College of Medicine, Given Building, 89 Beaumont Avenue, Burlington, Vermont, 05405, USA
Ann Surg Oncol 12:753-60. 2005..However, this method can result in false-positive staining events. We used multicolor immunofluorescence (IF) to develop a more specific assay for detecting isolated tumor cells in marrow samples from breast cancer patients...
- Increased mammography use and its impact on earlier breast cancer detection in Vermont, 1975-1999Pamela M Vacek
Department of Medical Biostatistics, University of Vermont, Burlington, Vermont 05405, USA
Cancer 94:2160-8. 2002..This study examined the effects of mammography on tumor size and axillary lymph node metastasis in Vermont over 25 years...
- Influence of breast cancer histology on the relationship between ultrasound and pathology tumor size measurementsBobbi Pritt
Department of Pathology, University of Vermont College of Medicine, Burlington, VT 05405 0068, USA
Mod Pathol 17:905-10. 2004..Pathologic tumor size can be estimated from the ultrasonographic measurement, particularly if the histologic tumor subtype is known. The results of this study underscore the continued benefit of pretreatment tumor histology...
- Pathological evaluation of sentinel lymph nodes in breast cancer: a practical academic perspective from AmericaD L Weaver
Department of Pathology, Health Sciences Complex, University of Vermont College of Medicine, Burlington 05405 0068, USA
Histopathology 46:702-6. 2005
- Phage-displayed random peptide libraries in mice: toxicity after serial panningDavid N Krag
Department of Surgery, College of Medicine and the Vermont Comprehensive Cancer Center, Given Bldg Rm E309, Burlington, VT 05405, USA
Cancer Chemother Pharmacol 50:325-32. 2002..With the ultimate goal of developing similar methods for treating human cancer, we describe an in vivo RPL screening process that, unlike previous in vivo experiments, does not harm the animal being screened...
- Carcinoma and atypical hyperplasia in reduction mammaplasty: increased sampling leads to increased detection. A prospective studyAbiy B Ambaye
Department of Pathology, Vermont Cancer Center, University of Vermont, Burlington, VT, USA
Plast Reconstr Surg 124:1386-92. 2009..Systematic sampling of additional tissue sections was instituted to evaluate the hypothesis that increased sampling would identify more significant pathologic findings...
- Revision of the American Joint Committee on Cancer staging system for breast cancerS Eva Singletary
University of Texas M D Anderson Cancer Center and Baylor College of Medicine, Houston, TX, USA
J Clin Oncol 20:3628-36. 2002..To revise the American Joint Committee on Cancer staging system for breast carcinoma...
- American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancerGary H Lyman
University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
J Clin Oncol 23:7703-20. 2005..To develop a guideline for the use of sentinel node biopsy (SNB) in early stage breast cancer...
- Occult "micrometastases" in ductal carcinoma in situ: investigative implications for sentinel lymph node biopsyDonald L Weaver
Cancer 98:2083-7. 2003
- Performance of diagnostic mammography for women with signs or symptoms of breast cancerWilliam E Barlow
W E Barlow, Center for Health Studies, Group Health Cooperative, Department of Biostatistics, University of Washington, Seattle 98101 1448, USA
J Natl Cancer Inst 94:1151-9. 2002..We evaluated whether age, breast density, self-reported breast lump, and previous mammography influence the performance of diagnostic mammography...
- Detection of ductal carcinoma in situ in women undergoing screening mammographyVirginia L Ernster
Department of Epidemiology and Biostatistics, School of Medicine, University of California, San Francisco, USA
J Natl Cancer Inst 94:1546-54. 2002..We pooled data from seven regional mammography registries to determine the percentage of mammographically detected cancers that are DCIS and the rate of DCIS per 1000 mammograms...
- Comparing screening mammography for early breast cancer detection in Vermont and NorwaySolveig Hofvind
Department of Screening based Research, The Cancer Registry of Norway, Oslo, Norway
J Natl Cancer Inst 100:1082-91. 2008..We examined how these differences affect early detection of breast cancer by comparing performance measures and histopathologic outcomes in women undergoing opportunistic screening in Vermont and organized screening in Norway...
- Is mode of breast cancer detection associated with cancer treatment in the United States?K Robin Yabroff
Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD 20892 7344, USA
Cancer 112:1011-9. 2008..In the current study, the authors explored whether detection by mammography was associated with greater use of guideline-consistent breast cancer treatment among patients with recently diagnosed breast cancer in the United States...
- The TNM staging system and breast cancerJohn R Benson
Cambridge Breast Unit, Addenbrooke s Hospital, Cambridge, UK
Lancet Oncol 4:56-60. 2003
- Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging ManualS Eva Singletary
Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 106, Houston, TX 77030 4009, USA
Surg Clin North Am 83:803-19. 2003..By increasing the number of prognostic markers that can give independent information about patient outcome, physicians will be better able to determine optimal treatment approaches for individual patients...
- Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened populationKarla Kerlikowske
San Francisco Veterans Affairs Medical Center, General Internal Medicine Section, 111A1, 4150 Clement St, San Francisco, CA 94121, USA
J Clin Oncol 21:4314-21. 2003..We determined the risk of breast cancer and tumor characteristics among current postmenopausal hormone therapy users compared with nonusers, by duration of use...
- Factors associated with imaging and procedural events used to detect breast cancer after screening mammographyPatricia A Carney
Norris Cotton Cancer Center, Dartmouth Medical School, Lebanon, NH 03756, USA
AJR Am J Roentgenol 188:385-92. 2007..The purpose of this study was to characterize the type and frequency of diagnostic evaluations after screening mammography and to summarize their association with the likelihood of biopsy and subsequent breast cancer diagnosis...
- Effect of breast augmentation on the accuracy of mammography and cancer characteristicsDiana L Miglioretti
Center for Health Studies, Group Health Cooperative, Department of Biostatistics, University of Washington, Seattle, Wash 98101, USA
JAMA 291:442-50. 2004..Breast augmentation is not associated with an increased risk of breast cancer; however, implants may interfere with the detection of breast cancer thereby delaying cancer diagnosis in women with augmentation...
- Performance benchmarks for screening mammographyRobert D Rosenberg
Department of Radiology, University of New Mexico Health Sciences Center, MSC10 5530, USA
Radiology 241:55-66. 2006..S. radiologists to allow development of performance benchmarks for screening mammography...
- Assessing the significance of occult micrometastases in axillary lymph nodes from breast cancer patientsDonald L Weaver
Breast J 12:291-3. 2006
- Prerandomization Surgical Training for the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-32 trial: a randomized phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node-negative breSeth P Harlow
Department of Surgery, University of Vermont College of Medicine and the Vermont Cancer Center, Burlington 05405, USA
Ann Surg 241:48-54. 2005..To train surgeons in a standardized technique of sentinel lymph node biopsy and to prepare them for the requirements of a prospective randomized surgical trial...
- The frequency of ipsilateral second tumors after breast-conserving surgery for DCIS: a population based analysisJoan L Warren
Health Services and Economics Branch Applied Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland 20892 7344, USA
Cancer 104:1840-8. 2005..This analysis of women treated with breast-conserving surgery (BCS) evaluated the impact of radiation therapy (RT) in patient outcomes...
- Association between breast density and subsequent breast cancer following treatment for ductal carcinoma in situE Shelley Hwang
Department of Surgery, University of California, San Francisco Cancer Center, 1600 Divisadero Avenue, B606 San Francisco, CA 94115, USA
Cancer Epidemiol Biomarkers Prev 16:2587-93. 2007..All subjects had an American College of Radiology Breast Imaging Reporting and Data System (BI-RADS) breast density measure recorded prior to diagnosis...